Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $77.4 million.

  • Amylyx Pharmaceuticals' Cash & Equivalents rose 213.45% to $225.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.2 million, marking a year-over-year increase of 213.45%. This contributed to the annual value of $77.4 million for FY2024, which is 54.53% down from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Cash & Equivalents is $77.4 million, which was down 54.53% from $170.2 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Cash & Equivalents' 5-year high stood at $170.2 million during FY2023, with a 5-year trough of $50.2 million in FY2021.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Cash & Equivalents value was $77.4 million (recorded in 2024), while the average stood at $103.4 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Cash & Equivalents spiked by 172.21% in 2023 and then tumbled by 54.53% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Cash & Equivalents (Yearly) stood at $50.2 million in 2021, then grew by 24.58% to $62.5 million in 2022, then soared by 172.21% to $170.2 million in 2023, then plummeted by 54.53% to $77.4 million in 2024.